RE: The company owes an RNS response5 May 2021 11:01
what the point, most of india live below the poverty line, earning less than $1 a day. they are not going to spend $3k on a treatment for their population.
This is probably the issue, countries that can afford this drug are rolling out vaccines, UK, US, etc. Those that can't afford, like India, won't buy it.
So i've been invested a while now and seen 40p to 120p. Like most i've been holding out for April - the month of 2m tests a week and big gov contract news. the in-between RNS have all been good but we all know that this wont rocket till contracts are announced.
What had me thinking is i was also invested in NCYT (now out) and they had recent issues with gov regarding their contract. Where as last year contracts were awarded like confetti, but now they seem to be back tracking somewhat. Are we now seeing this issue affecting ODX? maybe the gov have over promised what they are willing to offer and this is the possible delay?
they cant seem to decide what test they want either.